Name: Europe Liver Cancer Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)
Brand: DataM Intelligence
SKU: PH6223
Price: 3750 USD
Availability: InStock

Europe Liver Cancer Therapeutics Market Size Share & Report 2024-2031

Europe Liver Cancer Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

<h2>Europe Liver Cancer Therapeutics Market Is Segmented By Type (Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, Others), By Therapy Type (Targeted Therapy, Radiation Therapy, Immunotherapy, Chemotherapy), By End User (Hospitals And Clinics, Ascs, Cancer Rehabilitation Centers), By Country(Germany, U.K, France, Italy, Spain) &ndash; Share, Size, Outlook, And Opportunity Analysis, 2024-2031</h2>

&nbsp;

<h2>Europe Liver Cancer Therapeutics Market Overview</h2>

<blockquote>
The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022&nbsp;and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2024-2031).
</blockquote>

Liver cancer is a chronic, life-threatening, advanced condition that initiates in liver cells. The liver is the critical organ in the human body, found in the upper right of the abdomen underneath the right of the lungs. The liver produces enzymes and bile to digest food. It also delivers blood-clotting proteins and clarifies the blood by removing harmful materials.

<h2>Europe Liver Cancer Therapeutics Market Report Scope</h2>

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			&nbsp;8.95%
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Type,&nbsp;By Therapy Type, By End User,&nbsp;and By Country
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Country
			</td>
			<td>
			Germany
			</td>
		</tr>
	</tbody>
</table>

<h3>&nbsp;</h3>

To get a Free Sample Click Here

&nbsp;

<h2>Europe Liver Cancer Therapeutics Market Dynamics</h2>

Market drivers include the availability of novel drugs, a strong pipeline basis, and growing efforts for early diagnosis of HCC. Unhealthy lifestyles and a growing geriatric population are driving the growth of the liver cancer therapeutics market.&nbsp;

The growing cases of liver cancer drive Europe&rsquo;s market growth.

According to the European Commission, around three-quarters of European liver cancer patients are of a kind known as hepatocellular carcinoma, which, when analyzed late, sees only one in 10 victims survive five years or more. Also, according to the European Association for the Study of the Liver, more than 98,000 persons in Europe are diagnosed with liver cancer yearly, while around 89,000 die from it. Late diagnosis is a serious problem, as up to half of the patients are diagnosed with an advanced cancer stage. Therefore, prevention and early detection are crucial to beat liver cancer.&nbsp; According to Global Policy Reporting, there has been a 70% increase in liver cancer-related mortality in Europe in the past two decades. Over 87,000 Europeans were diagnosed with liver cancer, while 78,000 died in 2020.&nbsp;

Furthermore, different initiatives taken by various organizations to fight against Europe&#39;s liver cancer situation contribute towards market growth during the forecast period. For instance, In June 2021, EASL and the scientific liver health community in Europe called for implementing measures to improve liver cancer care in Europe. Also, Ambitious Europe&#39;s Beating Cancer Plan and the EU4Health program must be the basis for improving patients with liver cancer care. Thus, the growing cases of liver cancer and initiatives by European organizations to fight against liver cancer are promoting market growth in the forecast period.

The high cost of liver cancer diagnosis and treatment in Europe is restraining the Europe liver cancer therapeutics market growth.

However, the high cost of liver cancer diagnosis and treatment in Europe is hampering the market growth. For instance, according to Booking Health GmbH, the cost of treatment with chemoembolization starts at &euro;4,711. The price for unilateral hepatectomy starts at &euro;12,076. The cost of radiofrequency ablation starts at &euro;4,687.

<h2>COVID-19 Impact on&nbsp;Europe Liver Cancer Therapeutics Market&nbsp;</h2>

The prognosis of patients with HCC largely depends on the stage of underlying liver disease. Measures for the care of patients with the liver disease during the COVID-19 pandemic have recently been proposed by the European Association for the Studies of the Liver (EASL). Under this, the patients with decompensated liver disease, patients on the waiting list for liver transplantation, patients with suspected HCC, patients with proven HCC awaiting treatment initiation or modification, and patients showing moderate or severe side effects to treatment were kept on high priority. Such initiatives by European organizations to manage liver cancer patients during the pandemic lessened the negative impact of the pandemic on the market.

<h2>Europe Liver Cancer Therapeutics Segment Analysis</h2>

Chemotherapy is expected to have a greater grasp of the liver cancer therapeutics market during the forecast period (2022-2029)

The chemotherapy segment is anticipated to dominate the Europe Liver cancer therapeutics market, owing to the increased research activities focused on chemotherapy. For instance, according to an article from Pan European Networks Ltd, published in October 2022, a new drug discovered by the University of Barcelona can inhibit cell division and growth in enzymes and could revolutionize liver cancer treatment. Also, in January 2023, The European Medicines Agency&rsquo;s Committee for Medicinal Products for Human Use gave a positive opinion on the use of durvalumab (Imfinzi) combined with tremelimumab (Imjudo) to treat advanced lung and liver cancers, according to a press release from AstraZeneca. Therefore, the mentioned data indicates that the chemotherapy segment will dominate the Europe liver cancer therapeutics market during the forecast period.

<h2>Europe Liver Cancer Therapeutics Geographical Analysis</h2>

Germany is expected to command dominating the Europe liver cancer therapeutics market.&nbsp;

Germany is estimated to hold most of the Europe liver cancer therapeutics market in the forecast period, owing to the increasing research activities in this country and the growing liver cancer cases. For instance, in August 2022, Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Hebrew University in Jerusalem identified the cell of origin in mice of combined liver/biliary duct carcinomas, a rare type of cancer of the liver. The pro-inflammatory immune messenger interleukin 6 (IL-6) was found to be the driver of carcinogenesis. Blocking of IL-6 reduced both the number and size of tumors in mice. Moreover, According to The Robert Koch Institute, a Federal Institute within the Federal Ministry of Health portfolio, in Germany, there were about 9,500 new cases per year, with about 8,000 deaths. On average, men are diagnosed at 71 years and women at 75. Thus, the mentioned data indicates that Germany will hold most of the Europe liver cancer therapeutics market throughout the forecast period.

<h2>Europe Liver Cancer Therapeutics&nbsp;Competitive Landscape</h2>

The key players operating in the Europe Liver Cancer Therapeutics market are Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, and UCB SA. among others. The key players are embracing various strategies such as product launches, mergers &amp; acquisitions, partnerships, and collaborations, contributing to the growth of the Liver Cancer Therapeutics market in Europe. For instance, in December 2022, AstraZeneca&rsquo;s Imfinzi (durvalumab) was approved in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin).

Amgen Inc.

Overview:&nbsp;

Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures, and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and innovates novel medicines based on cellular and molecular biology advances.

Product Portfolio:

The Company&rsquo;s portfolio comprises inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas.

The Europe liver cancer therapeutics report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.&nbsp;

<ol>
	<li>
	<h3 style="color:#1e4d78; font-style:normal">&nbsp;Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1e4d78; font-style:normal">Market Definition and Overview</h3>
	</li>
	<li>
	<h3 style="color:#1e4d78; font-style:normal">Executive Summary</h3>
	</li>
	<li>
	<h3 style="color:#1e4d78; font-style:normal">Market Dynamics</h3>

	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>The Growing Cases of Liver Cancer&nbsp;</li>
				<li>&nbsp;Market Developments​&nbsp;</li>
			</ol>
			</li>
			<li>Restraints
			<ol>
				<li>High Cost of diagnosis and treatment</li>
				<li>Treatment Side Effects</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis&nbsp;</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1e4d78; font-style:normal">Industry Analysis&nbsp;</h3>

	<ol>
		<li>Porter&#39;s Five Forces Analysis&nbsp;</li>
		<li>Supply Chain Analysis</li>
		<li>Regulatory Analysis</li>
	</ol>
	</li>
	<li>COVID-19 Analysis
	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During the Pandemic</li>
		<li>Manufacturer&rsquo;s Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1e4d78; font-style:normal">By Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Attractiveness Index, By Type</li>
		</ol>
		</li>
		<li>Hepatocellular Carcinoma
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Cholangio Carcinoma</li>
		<li>Hepatoblastoma</li>
		<li>Other</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1e4d78; font-style:normal">By Therapy Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type&nbsp;</li>
			<li>Market Attractiveness Index, By Therapy Type&nbsp;</li>
		</ol>
		</li>
		<li>Targeted Therapy*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Radiation Therapy</li>
		<li>Immunotherapy</li>
		<li>Chemotherapy</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1e4d78; font-style:normal">By End User</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User&nbsp;</li>
			<li>Market Attractiveness Index, By End User&nbsp;</li>
		</ol>
		</li>
		<li>&nbsp;Hospitals And Clinics
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>ASCs</li>
		<li>Cancer Rehabilitation Centers</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1e4d78; font-style:normal">By Country</h3>

	<ol>
		<li>Introduction&nbsp;
		<ol>
			<li>Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Country</li>
			<li>Market Attractiveness Index, By Country</li>
		</ol>
		</li>
		<li>Germany
		<ol>
			<li>Introduction</li>
			<li>Key Country-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
		</ol>
		</li>
		<li>U.K.
		<ol>
			<li>Introduction</li>
			<li>Key Country-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
		</ol>
		</li>
		<li>France
		<ol>
			<li>Introduction</li>
			<li>Key Country-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
		</ol>
		</li>
		<li>Italy
		<ol>
			<li>Introduction</li>
			<li>Key Country-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
		</ol>
		</li>
		<li>Spain
		<ol>
			<li>Introduction</li>
			<li>Key Country-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
		</ol>
		</li>
		<li>Rest of Europe
		<ol>
			<li>Introduction</li>
			<li>Key Country-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1e4d78; font-style:normal">Competitive Landscape</h3>

	<ol>
		<li>Key Developments and Strategies&nbsp;</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1e4d78; font-style:normal">Company Profiles</h3>

	<ol>
		<li>Amgen Inc.&nbsp;
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>AstraZeneca PLC</li>
		<li>&nbsp;Bayer AG</li>
		<li>&nbsp;Celgene Corporation</li>
		<li>&nbsp;Eli Lilly</li>
		<li>Bristol-Myers Squibb Company</li>
		<li>&nbsp;Gilead Sciences, Inc.</li>
		<li>&nbsp;Takeda Pharmaceutical Company Limited</li>
		<li>&nbsp;Daiichi Sankyo Company, Limited</li>
		<li>&nbsp;UCB SA&nbsp;(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1e4d78; font-style:normal">DataM Intelligence</h3>

	<ol>
		<li>Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h3>List of Tables</h3>

Table No. 1 Europe Liver Cancer Therapeutics Market Value, By Type, 2021, 2025 &amp; 2029 ($ Million)

Table No. 2 Europe Liver Cancer Therapeutics Market Value, By Therapy Type, 2021, 2025 &amp; 2029 ($ Million)

Table No. 3 Europe Liver Cancer Therapeutics Market Value, By End User, 2021, 2025 &amp; 2029 ($ Million)

Table No. 4 Europe Liver Cancer Therapeutics Market Value, By Country, 2021, 2025 &amp; 2029 ($ Million)

Table No. 5 Europe Liver Cancer Therapeutics Market Value, By Type, 2021, 2025 &amp; 2029 ($ Million)

Table No. 6 Europe Liver Cancer Therapeutics Market Value, By Type, 2021-2030 ($ Million)

Table No. 7 Europe Liver Cancer Therapeutics Market Value, By Therapy Type, 2021, 2025 &amp; 2029 ($ Million)

Table No. 8 Europe Liver Cancer Therapeutics Market Value, By Therapy Type, 2021-2030 ($ Million)

Table No. 9 Europe Liver Cancer Therapeutics Market Value, By End User, 2021, 2025 &amp; 2029 ($ Million)

Table No. 10 Europe Liver Cancer Therapeutics Market Value, By End User, 2021-2030 ($ Million)

Table No. 11 Europe Liver Cancer Therapeutics Market Value, By Country, 2021, 2025 &amp; 2029 ($ Million)

Table No. 12 Europe Liver Cancer Therapeutics Market Value, By Country, 2021-2030 ($ Million)

Table No. 13 Germany Liver Cancer Therapeutics Market Value, By Type, 2021-2030 ($ Million)

Table No. 14 Germany Liver Cancer Therapeutics Market Value, By Therapy Type, 2021-2030 ($ Million)

Table No. 15 Germany Liver Cancer Therapeutics Market Value, By End User, 2021-2030 ($ Million)

Table No. 16 The U.K. Liver Cancer Therapeutics Market Value, By Type, 2021-2030 ($ Million)

Table No. 17 The U.K. Liver Cancer Therapeutics Market Value, By Therapy Type, 2021-2030 ($ Million)

Table No. 18 The U.K. Liver Cancer Therapeutics Market Value, By End User, 2021-2030 ($ Million)

Table No. 19 France Liver Cancer Therapeutics Market Value, By Type, 2021-2030 ($ Million)

Table No. 20 France Liver Cancer Therapeutics Market Value, By Therapy Type, 2021-2030 ($ Million)

Table No. 21 France Liver Cancer Therapeutics Market Value, By End User, 2021-2030 ($ Million)

Table No. 22 Italy Liver Cancer Therapeutics Market Value, By Type, 2021-2030 ($ Million)

Table No. 23 Italy Liver Cancer Therapeutics Market Value, By Therapy Type, 2021-2030 ($ Million)

Table No. 24 Italy Liver Cancer Therapeutics Market Value, By End User, 2021-2030 ($ Million)

Table No. 25 Spain Liver Cancer Therapeutics Market Value, By Type, 2021-2030 ($ Million)

Table No. 26 Spain Liver Cancer Therapeutics Market Value, By Therapy Type, 2021-2030 ($ Million)

Table No. 27 Spain Liver Cancer Therapeutics Market Value, By End User, 2021-2030 ($ Million)

Table No. 28 Rest of Europe Liver Cancer Therapeutics Market Value, By Type, 2021-2030 ($ Million)

Table No. 29 Rest of Europe Liver Cancer Therapeutics Market Value, By Therapy Type, 2021-2030 ($ Million)

Table No. 30 Rest of Europe Liver Cancer Therapeutics Market Value, By End User, 2021-2030 ($ Million)

Table No. 31 Amgen Inc.: Overview

Table No. 32 Amgen Inc.: Product Portfolio

Table No. 33 Amgen Inc.: Key Developments

Table No. 34 AstraZeneca PLC: Overview

Table No. 35 AstraZeneca PLC: Product Portfolio

Table No. 36 AstraZeneca PLC: Key Developments

Table No. 37 Bayer AG: Overview

Table No. 38 Bayer AG: Product Portfolio

Table No. 39 Bayer AG: Key Developments

Table No. 40 &nbsp;Celgene Corporation: Overview

Table No. 41 &nbsp;Celgene Corporation: Product Portfolio

Table No. 42 &nbsp;Celgene Corporation: Key Developments

Table No. 43 &nbsp;Eli Lilly: Overview

Table No. 44 &nbsp;Eli Lilly: Product Portfolio

Table No. 45 &nbsp;Eli Lilly: Key Developments

Table No. 46 Bristol-Myers Squibb Company: Overview

Table No. 47 Bristol-Myers Squibb Company: Product Portfolio

Table No. 48 Bristol-Myers Squibb Company: Key Developments

Table No. 49 &nbsp;Gilead Sciences, Inc.: Overview

Table No. 50 &nbsp;Gilead Sciences, Inc.: Product Portfolio

Table No. 51 &nbsp;Gilead Sciences, Inc.: Key Developments

Table No. 52 &nbsp;Takeda Pharmaceutical Company Limited: Overview

Table No. 53 &nbsp;Takeda Pharmaceutical Company Limited: Product Portfolio

Table No. 54 &nbsp;Takeda Pharmaceutical Company Limited: Key Developments

Table No. 55 &nbsp;Daiichi Sankyo Company, Limited: Overview

Table No. 56 &nbsp;Daiichi Sankyo Company, Limited: Product Portfolio

Table No. 57 &nbsp;Daiichi Sankyo Company, Limited: Key Developments

Table No. 58 &nbsp;UCB SA: Overview

Table No. 59 &nbsp;UCB SA: Product Portfolio

Table No. 60 &nbsp;UCB SA: Key Developments

<h3>List of Figures</h3>

Figure No. 1 Europe Liver Cancer Therapeutics Market Share, By Type, 2022 &amp; 2030 (%)

Figure No. 2 Europe Liver Cancer Therapeutics Market Share, By Therapy Type, 2022 &amp; 2030 (%)

Figure No. 3 Europe Liver Cancer Therapeutics Market Share, By End User, 2022 &amp; 2030 (%)

Figure No. 4 Europe Liver Cancer Therapeutics Market Share, By Country, 2022 &amp; 2030 (%)

Figure No. 5 Europe Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 6 Europe Liver Cancer Therapeutics Market Y-o-Y Growth, By Type, 2021-2029 (%)

Figure No. 7 Hepatocellular Carcinoma: Europe Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 8 Cholangio Carcinoma: Europe Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 9 Hepatoblastoma: Europe Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 10 Other: Europe Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 11 Europe Liver Cancer Therapeutics Market Y-o-Y Growth, By Therapy Type, 2021-2029 (%)

Figure No. 12 Targeted Therapy: Europe Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 13 Radiation Therapy: Europe Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 14 Immunotherapy: Europe Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 15 Chemotherapy: Europe Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 16 Europe Liver Cancer Therapeutics Market Y-o-Y Growth, By End User, 2021-2029 (%)

Figure No. 17 Hospitals And Clinics: Europe Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 18 ASCs: Europe Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 19 Cancer Rehabilitation Centers: Europe Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 20 Europe Liver Cancer Therapeutics Market Y-o-Y Growth, By Country, 2021-2029 (%)

Figure No. 21 Germany Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 22 Germany Liver Cancer Therapeutics Market Share, By Type, 2022 &amp; 2030 (%)

Figure No. 23 Germany Liver Cancer Therapeutics Market Share, By Therapy Type, 2022 &amp; 2030 (%)

Figure No. 24 Germany Liver Cancer Therapeutics Market Share, By End User, 2022 &amp; 2030 (%)

Figure No. 25 The U.K. Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 26 The U.K. Liver Cancer Therapeutics Market Share, By Type, 2022 &amp; 2030 (%)

Figure No. 27 The U.K. Liver Cancer Therapeutics Market Share, By Therapy Type, 2022 &amp; 2030 (%)

Figure No. 28 The U.K. Liver Cancer Therapeutics Market Share, By End User, 2022 &amp; 2030 (%)

Figure No. 29 Europe Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 30 France Liver Cancer Therapeutics Market Share, By Type, 2022 &amp; 2030 (%)

Figure No. 31 France Liver Cancer Therapeutics Market Share, By Therapy Type, 2022 &amp; 2030 (%)

Figure No. 32 France Liver Cancer Therapeutics Market Share, By End User, 2022 &amp; 2030 (%)

Figure No. 33 Italy Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 34 Italy Liver Cancer Therapeutics Market Share, By Type, 2022 &amp; 2030 (%)

Figure No. 35 Italy Liver Cancer Therapeutics Market Share, By Therapy Type, 2022 &amp; 2030 (%)

Figure No. 36 Italy Liver Cancer Therapeutics Market Share, By End User, 2022 &amp; 2030 (%)

Figure No. 37 Spain Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 38 Spain Liver Cancer Therapeutics Market Share, By Type, 2022 &amp; 2030 (%)

Figure No. 39 Spain Liver Cancer Therapeutics Market Share, By Therapy Type, 2022 &amp; 2030 (%)

Figure No. 40 Spain Liver Cancer Therapeutics Market Share, By End User, 2022 &amp; 2030 (%)

Figure No. 41 Rest of Europe Liver Cancer Therapeutics Market Value, 2021-2030 ($ Million)

Figure No. 42 Rest of Europe Liver Cancer Therapeutics Market Share, By Type, 2022 &amp; 2030 (%)

Figure No. 43 Rest of Europe Liver Cancer Therapeutics Market Share, By Therapy Type, 2022 &amp; 2030 (%)

Figure No. 44 Rest of Europe Liver Cancer Therapeutics Market Share, By End User, 2022 &amp; 2030 (%)

Figure No. 45 Amgen Inc.: Financials

Figure No. 46 AstraZeneca PLC: Financials

Figure No. 47 Bayer AG: Financials

Figure No. 48 &nbsp;Celgene Corporation: Financials

Figure No. 49 &nbsp;Eli Lilly: Financials

Figure No. 50 Bristol-Myers Squibb Company: Financials

Figure No. 51 &nbsp;Gilead Sciences, Inc.: Financials

Figure No. 52 &nbsp;Takeda Pharmaceutical Company Limited: Financials

Figure No. 53 &nbsp;Daiichi Sankyo Company, Limited: Financials

Figure No. 54 &nbsp;UCB SA: Financials